Impact of low-dose ritonavir on danoprevir pharmacokinetics: Results of computer-based simulations and a clinical drug-drug interaction study

Clinical Pharmacokinetics

Volumn 51, Issue 7, 2012, Pages 457-465

  Reddy, Micaela B ^a   Chen, Yuan ^b   Haznedar, Joshua Ö ^b   Fretland, Jennifer ^a   Blotner, Steven ^a   Smith, Patrick ^a   Tran, Jonathan Q ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

danoprevir; drug interactions; Hepatitis C virus NS3 protein inhibitors; HIV protease inhibitors; pharmacokinetic modelling; pharmacokinetics; ritonavir

Indexed keywords

DANOPREVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; COMPUTER SIMULATION; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; LACTAMS; MALE; MODELS, BIOLOGICAL; PROTEASE INHIBITORS; RITONAVIR; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84861692189     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11599700-000000000-00000     Document Type: Article

References (32)

1. Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008 Dec; 52 (12): 4432-41
2. Bradford WZ, Rubino C, Porter S, et al. A phase 1 study of the safety, tolerability, and pharmacokinetics of single ascending oral doses of the NS3/4A protease inhibitor ITMN-191 in healthy subjects [abstract]. Hepatology 2008 Oct; 48 Suppl. 1: 1146A
3. Rubino C, Bradford WZ, Forrest A, et al. Pharmacokinetic-pharmacodynamic (PK-PD) relationships for ITMN-191 in a phase 1 multiple ascending dose trial in patients with genotype 1 chronic hepatitis C infection [abstract]. Hepatology 2008 Oct; 48 Suppl. 2: 1140A-1A
4. Forestier N, Larrey DG, Guyader D, et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 2011 Jun; 54: 1130-6
5. ForestierN, LarreyD,Marcellin P, et al.Antiviral activity and safety of ITMN-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic C virus (HCV) [abstract]. J Hepatol 2009; 50 Suppl. 1: S35
6. Terrault N, Cooper C, Balart LA, et al. Phase II randomised, partially-blind, parallel-group study of oral danoprevir (RG7227) with PegIFN a-2a (PEGASYS) plus ribavirin in treatment-naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study [abstract]. Hepatology 2010 Oct; 52 Suppl. 4: 335A
7. Levi M, Frey N, Hsu JC, et al. High exposure to danoprevir (RG7227) increases the probability of ALT elevations in patients treated with danoprevir plus peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin [abstract]. Hepatology 2010 Oct; 52 Suppl. 4: 1216A
8. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004 Jan; 53 (1): 4-9 (Pubitemid 38072176)
9. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001 Apr; 2 (2): 105-13 (Pubitemid 33114749)
10. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008 Jul; 42 (7): 1048-59
11. Data on file, Roche, 2009
12. Grime KH, Bird J, Ferguson D, et al. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 2009 Feb 15; 36 (2-3): 175-91
13. Simcyp. A guide for IVIVE and PBPK modelling using the Simcyp populationbased ADME simulator. Sheffield: Simcyp Limited, 2010: 394
14. Yang JS, Jamei M, Yeo KR, et al. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007 Oct; 8: 676-84 (Pubitemid 47578116)
15. Gao H, Steyn SJ, Chang G, et al. Assessment of in silico models for fraction of unbound drug in human liver microsomes. Expert Opin Drug Metab Toxicol 2010 May; 6 (5): 533-42
16. Turner DB, Yeo KR, Tucker GT, et al. Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties [abstract no. A231]. Drug Metab Rev 2006; 38 (1): 162
17. Cozza KL, Armstrong SC, Oesterheld JR. Concise guide to drug interaction principles for medical practice: cytochrome P450s, UGTs, P-glycoproteins. Arlington (VA): American Psychiatric Publishing, 2003 Jan
18. Almond L, Yeo KR, Howgate E, et al. Mechanistic prediction of HIV drugdrug interactions in virtual populations from in vitro enzyme kinetic data: ritonavir and saquinavir. International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, 16th-18th April 2007 [online]. Available from URL: http://www.simcyp.com/UploadedFiles/154/Lisa-Almond-2007-Budapest-SQVr- finalised.pdf [Accessed 2011 Nov 10]
19. Hyland R, Dickins M, Collins C, et al. Maraviroc: in vitro assessment of drugdrug interaction potential. Br J Clin Pharmacol 2008 Oct; 66: 498-507
20. Annaert P, Ye ZW, Stieger B, et al. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 2010; 40: 163-76
21. Jackson A, Watson V, Back D, et al. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr 2011 Dec 15; 58 (5): 450-7
22. Wang YH. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. DrugMetab Dispos 2010 Apr; 38: 1094-104
23. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN a-2a/RBV in hepatitis C patients. J Hepatol 2011 Nov; 55 (5): 972-9
24. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 4th ed. Stockholm: Swedish Pharmaceutical Press, 2007 Jul
25. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010 Mar; 87 (3): 322-9
26. Hill A, van der Lugt J, SawyerW, et al. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 2009 Nov 13; 23 (17): 2237-45
27. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998 Oct; 35: 275-91 (Pubitemid 28491214)
28. Kenny JR, McGinnity DF, Grime K, et al. Utilization of in vitro cytochrome P450 inhibition data for projecting clinical drug-drug interactions. In: Gad SC, editor. Preclinical development handbook: ADME and biopharmaceutical properties. Hoboken (NJ): Wiley, 2008 Aug: 775-828
29. Poirier A, Cascais AC, Funk C, et al. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 2009; 36: 585-611
30. Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 2010 Dec; 37 (6): 575-90
31. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006 Oct; 131: 997-1002 (Pubitemid 44498690)
32. Forestier N, Larrey D, Marcellin P, et al. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon a-2a and ribavirin in patients with hepatitis C. J Infect Dis 2011 Aug; 204: 601-8